Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.

Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, Rodman JH, Chen J, Palumbo P, Serchuck L, Smith E, Hughes M; P1030 team.

AIDS. 2008 Jan 11;22(2):249-55.

PMID:
18097227
2.

High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis.

Mphatswe W, Blanckenberg N, Tudor-Williams G, Prendergast A, Thobakgale C, Mkhwanazi N, McCarthy N, Walker BD, Kiepiela P, Goulder P.

AIDS. 2007 Jun 19;21(10):1253-61.

PMID:
17545701
3.

Response to antiretroviral therapy after a single, peripartum dose of nevirapine.

Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, Ndase P, Arimi P, van Widenfelt E, Mazhani L, Novitsky V, Lagakos S, Essex M.

N Engl J Med. 2007 Jan 11;356(2):135-47.

4.

CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation?

Newell ML, Patel D, Goetghebuer T, Thorne C; European Collaborative Study.

J Infect Dis. 2006 Apr 1;193(7):954-62. Epub 2006 Feb 23.

PMID:
16518757
5.

Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data.

HIV Paediatric Prognostic Markers Collaborative Study.

Lancet. 2005 Nov 26;366(9500):1868-74.

PMID:
16310553
6.

Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age.

Chadwick EG, Rodman JH, Britto P, Powell C, Palumbo P, Luzuriaga K, Hughes M, Abrams EJ, Flynn PM, Borkowsky W, Yogev R; PACTG Protocol 345 Team.

Pediatr Infect Dis J. 2005 Sep;24(9):793-800.

PMID:
16148846
7.

Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis.

Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F; Ghent International AIDS Society (IAS) Working Group on HIV Infection in Women and Children.

Lancet. 2004 Oct 2-8;364(9441):1236-43.

PMID:
15464184
8.

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.

Sáez-Llorens X, Violari A, Deetz CO, Rode RA, Gomez P, Handelsman E, Pelton S, Ramilo O, Cahn P, Chadwick E, Allen U, Arpadi S, Castrejón MM, Heuser RS, Kempf DJ, Bertz RJ, Hsu AF, Bernstein B, Renz CL, Sun E.

Pediatr Infect Dis J. 2003 Mar;22(3):216-24.

PMID:
12634581
9.

Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.

Capparelli EV, Sullivan JL, Mofenson L, Smith E, Graham B, Britto P, Becker MI, Holland D, Connor JD, Luzuriaga K; Pediatric ACTG 356 Investigators.

Pediatr Infect Dis J. 2001 Aug;20(8):746-51.

PMID:
11734735
10.

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White AC Jr, Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A, Sun E.

AIDS. 2001 Jan 5;15(1):F1-9.

PMID:
11192874
11.

Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories.

Yen-Lieberman B, Brambilla D, Jackson B, Bremer J, Coombs R, Cronin M, Herman S, Katzenstein D, Leung S, Lin HJ, Palumbo P, Rasheed S, Todd J, Vahey M, Reichelderfer P.

J Clin Microbiol. 1996 Nov;34(11):2695-701.

Supplemental Content

Support Center